Panacea Global Enlists Maxim Group as Financial Advisor and Investment Banker
Wed, 28 May 2014
TORONTO, ONTARIO, May 28, 2014 (Marketwired via COMTEX) — Panacea Global Inc. PANG -10.33% , ( www.panaceaglobalinc.com ) (“Panacea Global” or “the Company”) announced today that it has enlisted the services of Maxim Group LLC, a leading investment banking, securities and investment management firm, to provide strategic corporate finance and investment banking services. Maxim will focus on assisting Panacea Global in its strategies for maximizing shareholder value through its full scope of investment banking services.
“We are looking forward to utilizing the expertise of Maxim Group to help Panacea Global effectively penetrate the global biotech market with our novel cancer diagnostics technology,” said Dr. Mahmood Moshiri, President and CEO of Panacea Global. “As we continue to demonstrate the value of our technology to high-growth markets around the world, we believe Maxim’s position as an investment banking firm concentrated on advising small-cap and midsized organizations will support our efforts to build upon our initial success.” Moshiri continued, “We trust Maxim will play a strong role of an advisor in executing organizational growth strategy to further enhance shareholder value.”
Maxim representatives commented, “We are delighted to partner with Panacea Global. Our goal will be to provide assistance to the Company in the financial and value creation components of its corporate strategy through our full-service investment banking capabilities. Furthermore, we will also be supporting Panacea Global in attaining its strategic initiatives and long-term objectives focused on building a cancer technology platform.”
About Panacea Global
Panacea Global is a biotechnology company focused on the development and commercialization of diagnostic products for the management of cancer. Panacea has developed an accurate, timely, cost effective and non-invasive early cancer detection test to increase the quality of life of cancer patients and ultimately saving lives. Panacea’s test is based on the detection of the human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a novel biomarker expressed in malignant cancer cells in patients’ blood samples. Panacea Global has the exclusive worldwide (excluding the USA) rights to HAAH-based cancer tests. Panacea Global Inc.’s shares are publicly traded on the OTCBB under the ticker symbol PANG in the US. More information about Panacea Global PANG -10.33% is available at www.panaceaglobalinc.com .
About Maxim Group:
Maxim Group LLC is a full-service investment banking firm headquartered in New York. Maxim Group provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales and trading as well as equity research. The investment banking group focuses on middle market and emerging growth companies within the shipping, energy, health care, technology, retail, and business and financial services sectors. The institutional coverage of Maxim Group spans North and South America, Europe and Asia. Maxim Group LLC is a registered as a broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc. To learn more about Maxim Group, visit www.maximgrp.com .
Safe Harbor Statement
Certain information contained in this document may include forward-looking information. Without limiting the foregoing, the information and any forward-looking information may include statements regarding projects, costs, objectives and future returns of the Company or hypotheses underlying these items. In this document, words such as may, would, could, will, likely, believe, expect, anticipate, intend, plan, estimate and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Forward-looking statements and information are based on information available at the time and/or the Company management’s good-faith beliefs with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company’s control. The Company does not intend, nor does it undertake, any obligation to update or revise any forward-looking information or statements contained in this document to reflect subsequent information, events or circumstances or otherwise, except as required by applicable laws.
Panacea Global Inc.